DexCom(DXCM) - 2025 Q4 - Annual Results

Financial Reporting - Dexcom will report preliminary, unaudited financial results for Q4 2025 and fiscal year 2025 on January 12, 2026[5]. - The preliminary results will include revenue growth rates and total revenue guidance for fiscal 2026[6]. - Dexcom's management will provide Non-GAAP Gross Profit Margin and Non-GAAP Operating Margin guidance for fiscal years 2025 and 2026[6]. - The financial results and outlook will be finalized in connection with the preparation of Dexcom's Annual Report on Form 10-K for the year ended December 31, 2025[6]. Business Updates - A business update press release was issued on January 7, 2026, providing additional context for the upcoming financial results[7]. - Dexcom's CEO, Jake Leach, will present the financial results at the J.P. Morgan 44th Annual Healthcare Conference[5]. Regulatory Compliance - The company is not classified as an emerging growth company under the Securities Act[3]. - Dexcom's financial statements and exhibits will be included in the filings as per the requirements of the Securities Exchange Act of 1934[9]. - The report will not be deemed "filed" for purposes of the Exchange Act, and the information is not incorporated by reference in any future filings[8]. Forward-Looking Statements - The company emphasizes that forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially[6].